Nasdaq
$34.60▲ 0.36%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.19BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 10.15After-hours26.10.16 05:178-KKey event#●●●#●●●
Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals approved the issuance of common stock in connection with its merger agreement at a special meeting of stockholders held on October 15, 2026. The proposal, which complies with Nasdaq Rule 5635, was passed with 85,455,705 votes in favor, representing a quorum of 77.27% of the 118,031,934 outstanding shares.…more
$34.60+0.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6Pre-market26.10.06 20:16425Other
Indivior Pharmaceuticals, Inc.
Indivior and Supernus have issued a supplement to their joint proxy statement/prospectus to address disclosure claims and litigation regarding their proposed merger. The supplement updates the financial analysis performed by Cantor Fitzgerald, including revised cash, debt, and share count figures, while confirming that the special stockholder meetings for both companies will proceed on October 15, 2026.…more
$34.60+0.36%vs prev closeView filingShare - 10.6Pre-market26.10.06 20:158-KKey event
Indivior Pharmaceuticals, Inc.
Indivior has issued a supplemental disclosure to its joint proxy statement/prospectus regarding its merger with Supernus Pharmaceuticals, following legal complaints from stockholders. This update provides additional details on the financial data and share count calculations used in the valuation analysis, while confirming that both companies will proceed with their special stockholder meetings on October 15, 2026.…more
$34.60+0.36%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.19 21:30#●●●
Indivior to Report Third Quarter 2026 Financial Results
Indivior announced that it will release its financial results for the third quarter of 2026 on October 29. This is a standard schedule announcement and does not contain specific financial data.…more
$34.60+0.36%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 20:00
●●●●●●●● ●●●●● ●●●●●●
Indivior has declared a special cash dividend of $8.13 per share, payable upon the successful closing of its merger with Supernus Pharmaceuticals. The dividend payment is strictly contingent upon the completion of the merger and necessary shareholder approvals.…more
$34.60+0.36%vs prev close - 9.15After-hours26.09.16 05:32
●●●●●●●● ●●●●● ●●●●●●
Indivior announced the accelerated termination of its supply agreement with Reckitt Benckiser for Suboxone and Subutex tablets, effective January 15, 2027. The company stated that it has already identified and secured a new supplier to replace the existing arrangement.…more
$34.60+0.36%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report